Guggenheim Reaffirms “Buy” Rating for Teva Pharmaceutical Industries Ltd. (TEVA)

Guggenheim reissued their buy rating on shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in a report released on Friday. The firm currently has a $80.00 target price on the stock…

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Spotlight

Resources